Therapy News and Research

RSS

Natural 'defence' gene reveals how oestrogen fuels cancer

CANCER RESEARCH UK scientists have shown for the first time how a natural 'defence' gene involved in fighting infections such as common colds, can be triggered by hormones to ignite and drive cancers like breast, ovarian, and possibly prostate cancer. Their findings are published in the Journal of Experimental Medicine.

13 Jan 2009

Researchers find molecular origin of blood stem cells

A research team led by Nancy Speck, PhD, Professor of Cell and Developmental Biology at the University of Pennsylvania School of Medicine, has identified the location and developmental timeline in which a majority of bone marrow stem cells form in the mouse embryo.

12 Jan 2009

HRT linked to brain shrinkage, but not lesions

Two new studies show that commonly prescribed forms of postmenopausal hormone therapy may slightly accelerate the loss of brain tissue in women 65 and older beyond what normally occurs with aging.

12 Jan 2009

Bristol-Myers Squibb and ZymoGenetics to collaborate on hepatitis C compound

Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.

12 Jan 2009

Discovery of better treatment for bacterial pneumonia

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.

9 Jan 2009

Use of robot and VR system improves walking post-stroke

Patients who've had a stroke and were rehabilitated using a robot to navigate virtual reality environments walked faster and a greater distance following physical therapy compared to those trained with the robot alone, according to researchers at the UMDNJ-School of Health Related Professions.

9 Jan 2009

Novel low-cost immunotherapy for cancer cells

Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others.

8 Jan 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

Estrogen plus progestin therapy may decrease risk of colorectal cancer

The combination of estrogen plus progestin, which women stopped taking in droves following the news that it may increase their risk of breast cancer, may decrease their risk of colorectal cancer, according to a report published in the January issue of Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.

8 Jan 2009

Growth of new brain cells requires 'epigenetic' switch

New cells are born every day in the brain's hippocampus, but what controls this birth has remained a mystery.

8 Jan 2009

Genta Incorporated issued two key U.S. patents for gallium products franchise

Genta Incorporated has announced that two new patents related to the Company's franchise in gallium-containing products have issued in the United States.

8 Jan 2009

Gene abnormality found to predict childhood leukemia relapse

Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).

8 Jan 2009

New avenue for TB therapy

Masses of immune cells that form as a hallmark of tuberculosis (TB) have long been thought to be the body's way of trying to protect itself by literally walling off the bacteria.

8 Jan 2009

Multifidus muscle design contributes to spine stability

The novel design of a deep muscle along the spinal column called the multifidus muscle may in fact be key to spinal support and a healthy back, according to researchers at the University of California, San Diego School of Medicine.

7 Jan 2009

Discovery of target that could ease spinal muscular atrophy symptoms

There is no cure for spinal muscular atrophy (SMA), a genetic disorder that causes the weakening of muscles and is the leading genetic cause of infant death, but University of Missouri researchers have discovered a new therapeutic target that improves deteriorating skeletal muscle tissue caused by SMA.

7 Jan 2009

New method for implanting aortic heart valves

An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center.

7 Jan 2009

Gene marker may improve odds of stem cell therapies for disease

A single tumor-suppressor gene may provide a unique marker for senescence in Mesenchymal stem cells (MSCs) in vitro, while also playing a role in moving MSCs into senescence, researchers at the Human Health Foundation and the Sbarro Institute for Cancer Research and Molecular Medicine report.

7 Jan 2009

Gene mutations found to predict acute lymphoblastic leukemia relapse

Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL).

7 Jan 2009

Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

7 Jan 2009

Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program

Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational.

6 Jan 2009